Co-Diagnostics, Inc. (CODX) — SEC Filings
Co-Diagnostics, Inc. (CODX) — 27 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 14 8-K, 6 10-Q, 3 DEF 14A.
View Co-Diagnostics, Inc. on SEC EDGAR
Overview
Co-Diagnostics, Inc. (CODX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Co-Diagnostics, Inc. filed an 8-K on December 5, 2025, reporting on the submission of matters to a vote of security holders. The filing details administrative information about the company, including its incorporation in Utah and its principal executive offices located at 2401 S. Foothill Drive, Sui
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 6 bearish, 21 neutral. The dominant filing sentiment for Co-Diagnostics, Inc. is neutral.
Filing Type Overview
Co-Diagnostics, Inc. (CODX) has filed 14 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 1 8-K/A, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of CODX's 25 recent filings, 4 were flagged as high-risk, 14 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $358,567 |
| Net Income | -$21,150,211 |
| EPS | -$0.62 |
| Debt-to-Equity | N/A |
| Cash Position | $11,443,943 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Chief Executive Officer
- Dwight H. Egan
- Brian Brown
- Dr. Mark R. Mitchell
- Dr. Richard K. Smith
- Ms. Sarah J. Smith
Industry Context
The diagnostics industry is highly competitive, driven by innovation in molecular diagnostics, genetic testing, and point-of-care solutions. Companies face pressure from established players and emerging startups. Regulatory hurdles, such as FDA approvals, are significant barriers to entry and market expansion. The shift towards personalized medicine and increased demand for rapid diagnostic tests are key trends.
Top Tags
corporate-governance (4) · shareholder-vote (4) · material-agreement (4) · filing (3) · 10-Q (3) · Molecular Diagnostics (2) · Going Concern (2) · Revenue Decline (2) · Equity Financing (2) · Biotech (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $358,567 | 90.4% decrease for nine months ended September 30, 2025, compared to $3,765,835 in 2024 |
| Net Loss | $21,150,211 | For nine months ended September 30, 2025, compared to $26,607,816 in 2024 |
| Cash and Cash Equivalents | $11,443,943 | As of September 30, 2025, up from $2,936,544 at December 31, 2024 |
| Net Cash from Financing Activities | $4,842,198 | For nine months ended September 30, 2025, primarily from equity offerings |
| Revenue Decline | 90.4% | Percentage decrease in total revenue for nine months ended September 30, 2025 |
| Loss per common share (Basic and Diluted) | $0.62 | For nine months ended September 30, 2025, improved from $0.88 in 2024 |
| Total Operating Expenses | $23,902,154 | For nine months ended September 30, 2025, a 23.5% decrease from $31,196,065 in 2024 |
| Stock-based compensation expense | $1,956,078 | For nine months ended September 30, 2025, down from $4,116,475 in 2024 |
| Accumulated Deficit | $54,191,053 | As of September 30, 2025, increased from $33,040,842 at December 31, 2024 |
| Shares of Common Stock Outstanding | 60,892,582 | As of November 11, 2025 |
| Minimum bid price requirement | $1.00 | Nasdaq Listing Rule 5550(a)(2) for continued listing |
| Minimum reverse stock split ratio | 1-for-2 | Proposed range for the reverse stock split |
| Maximum reverse stock split ratio | 1-for-30 | Proposed range for the reverse stock split |
| Record Date | October 29, 2025 | Date for shareholders entitled to vote at the Special Meeting |
| Special Meeting Date | December 5, 2025 | Date of the Special Meeting of Shareholders |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Co-Diagnostics, Inc. (CODX)?
Co-Diagnostics, Inc. has 27 recent SEC filings from Feb 2024 to Dec 2025, including 14 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CODX filings?
Across 27 filings, the sentiment breakdown is: 6 bearish, 21 neutral. The dominant sentiment is neutral.
Where can I find Co-Diagnostics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Co-Diagnostics, Inc. (CODX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Co-Diagnostics, Inc.?
Key financial highlights from Co-Diagnostics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CODX?
The investment thesis for CODX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Co-Diagnostics, Inc.?
Key executives identified across Co-Diagnostics, Inc.'s filings include Chief Executive Officer, Dwight H. Egan, Brian Brown, Dr. Mark R. Mitchell, Dr. Richard K. Smith and 1 others.
What are the main risk factors for Co-Diagnostics, Inc. stock?
Of CODX's 25 assessed filings, 4 were flagged high-risk, 14 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Co-Diagnostics, Inc.?
Forward guidance and predictions for Co-Diagnostics, Inc. are extracted from SEC filings as they are enriched.